IDEX BIOMETRICS ASA
2.3.2021 07:58:30 CET | Globenewswire | Press release
Two primary insiders in IDEX Biometrics ASA acquired IDEX ADSs, Nasdaq ticker code IDBA, on 1 March 2021. One ADS (IDBA) represents 75 ordinary shares (IDEX). The ordinary shares in IDEX are listed on Oslo Børs, ticker code IDEX.
CEO Vince Graziani acquired 2,000 ADSs, which corresponds to 150,000 ordinary shares, at an average price of USD 28.80 per ADS.. After the transaction, Mr. Graziani holds the equivalent of 960,239 ordinary shares and 5,000,000 incentive subscription rights to ordinary shares in IDEX.
CFO Derek D’Antilio acquired 500 ADSs, which represent 37,500 ordinary shares, at an average price of USD 31.50 per ADS. After the transaction, Mr. D’Antilio holds the equivalent of 795,426 ordinary shares and 2,000,000 incentive subscription rights to ordinary shares in IDEX.
For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 918 00186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S3.10.2026 21:40:00 CEST | Press release
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Chery Group3.10.2026 14:28:18 CEST | Press release
FREELANDER Marks a New Chapter at Its Global Brand Launch in Abu Dhabi
Chery Group3.10.2026 14:16:10 CEST | Press release
FREELANDER Sets Out Its International Roadmap with a Phased Expansion from the Middle East
Chery Auto3.10.2026 10:47:01 CEST | Press release
LEPAS Enters Romania: LEPAS L8 PHEV Officially Launches as First Flagship Store Opens
Novo Nordisk A/S2.10.2026 22:53:42 CEST | Press release
Novo provides update on the denecimig Biologics License Application (BLA) in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
